---
title: "Spatial profiling links MET expression to immune exclusion and therapy response in HNSCC"
id: "medrxiv-13-deep-learning-based-spatial-profiling-identifies-met-associated-immune"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-13-deep-learning-based-spatial-profiling-identifies-met-associated-immune"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.26.26366494v1?rss=1"
published_at: "2026-10-28T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Spatial profiling links MET expression to immune exclusion and therapy response in HNSCC
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-13-deep-learning-based-spatial-profiling-identifies-met-associated-immune
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.26.26366494v1?rss=1)
- **Published At:** 2026-10-28T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study used deep learning–based spatial profiling to compare tumor immune microenvironments between Black/African American (BAA) and White-derived head and neck squamous cell carcinoma (**HNSCC**) specimens. - Investigators reported reduced **CD8⁺ T cell** infiltration and increased immune checkpoint expression in BAA-derived tumors versus White-derived tumors. - The study team observed elevated spatial **MET** expression in BAA-derived tumors; higher MET spatial expression co-occurred with reduced CD8⁺ T cell presence. - Across independent cohorts, data indicated a reproducible inverse relationship between MET expression and CD8⁺ T cell infiltration, suggesting a tumor-intrinsic MET–immune exclusion axis. - In a phase 2 clinical trial cohort treated with **pembrolizumab** plus **cabozantinib** (ClinicalTrials.gov: NCT03468218), authors noted higher predicted spatial MET expression associated with treatment response and improved clinical outcomes, an association strongest among BAA patients. - The study combined deep learning spatial maps, tissue microarrays, immunofluorescence validation, and public genomics (Cancer Genome Atlas) data; the source did not report specific model architectures, parameter settings, or numeric cohort sizes in the abstract. - The preprint is not peer reviewed; data are available on reasonable request from the authors. - Unresolved questions include mechanistic causality between MET expression and immune exclusion, whether MET-directed strategies will alter racial outcome disparities in prospective studies, and validation in larger, prospectively powered cohorts.
## Clinical Analysis & Structured Key Points
Deep Learning-Based Spatial Profiling Identifies MET-Associated Immune Exclusion and Therapeutic Vulnerability Underlying Racial Disparities in Head and Neck Cancer | medRxiv Skip to main content Deep Learning-Based Spatial Profiling Identifies MET-Associated Immune Exclusion and Therapeutic Vulnerability Underlying Racial Disparities in Head and Neck Cancer Xinyu Cui , Fanghui Chen , Ashley McCook-Veal , Yuan Liu , View ORCID Profile Nicole C. Schmitt , Christine H. Chung , Conor E. Steuer , Dong M. Shin , Nabil F. Saba , Yong Teng doi: https://doi.org/10.64898/2026.10.26.26366494 Xinyu Cui 1 Emory University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Fanghui Chen 1 Emory University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ashley McCook-Veal 1 Emory University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yuan Liu 1 Emory University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nicole C. Schmitt 1 Emory University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Nicole C. Schmitt Christine H. Chung 2 Moffitt Cancer Center Find this author on Google Scholar Find this author on PubMed Search for this author on this site Conor E. Steuer 1 Emory University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Dong M. Shin 1 Emory University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nabil F. Saba 1 Emory University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yong Teng 1 Emory University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: yong.teng{at}emory.edu Abstract Info/History Metrics Data/Code Preview PDF Abstract Black/African American (BAA) patients with head and neck squamous cell carcinoma (HNSCC) experience more aggressive disease and poorer survival outcomes than White patients; however, the tumor immune microenvironmental features underlying these racial disparities remain poorly characterized. Here, we identify MET as a potential molecular link between immune exclusion and therapeutic response associated with racial disparities in HNSCC. Compared with White-derived tumors, deep learning-based spatial profiling revealed a distinct immune landscape in BAA-derived tumors, characterized by reduced CD8⁺ T cell infiltration, increased immune checkpoint expression, and elevated spatial MET expression. Across independent cohorts, higher MET expression was consistently associated with reduced CD8⁺ T cell infiltration, supporting a relationship between MET-associated tumor biology and an immune-excluded tumor microenvironment. Importantly, in a phase 2 clinical trial cohort treated with pembrolizumab plus cabozantinib, higher predicted spatial MET expression was strongly associated with treatment response and improved clinical outcomes, with the association particularly pronounced among BAA patients. This study establishes a spatially resolved framework linking tumor-intrinsic MET expression with the immune microenvironment and therapeutic response, suggesting that MET-associated biology may contribute to racial disparities in HNSCC progression and treatment outcomes. Competing Interest Statement The authors have declared no competing interest. Clinical Trial NCT03468218 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was conducted at Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia, United States, with collaborating investigators at Moffitt Cancer Center, Tampa, Florida, United States, and Georgia Institute of Technology, Atlanta, Georgia, United States. Ethics oversight was provided by the Emory University Institutional Review Board. Ethical approval was granted. Clinical specimens for the tissue microarray cohort and immunofluorescence validation were collected with written informed consent under Emory University Institutional Review Board approved protocol IRB00003208. The phase 2 clinical trial of pembrolizumab plus cabozantinib (ClinicalTrials.gov NCT03468218 ) was approved by the Emory University Institutional Review Board, and all participants provided written informed consent. The Cancer Genome Atlas data were obtained from the publicly available Genomic Data Commons Data Portal. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the authors Funder Information Declared National Center for Advancing Translational Sciences , UL1TR002378 National Cancer Institute, https://ror.org/040gcmg81 , P30CA138292 Emory University School of Medicine, https://ror.org/001hz7s79 Woodruff Fund Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted October 28, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Deep Learning-Based Spatial Profiling Identifies MET-Associated Immune Exclusion and Therapeutic Vulnerability Underlying Racial Disparities in Head and Neck Cancer Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Deep Learning-Based Spatial Profiling Identifies MET-Associated Immune Exclusion and Therapeutic Vulnerability Underlying Racial Disparities in Head and Neck Cancer Xinyu Cui , Fanghui Chen , Ashley McCook-Veal , Yuan Liu , Nicole C. Schmitt , Christine H. Chung , Conor E. Steuer , Dong M. Shin , Nabil F. Saba , Yong Teng medRxiv 2026.10.26.26366494; doi: https://doi.org/10.64898/2026.10.26.26366494 Share This Article: Copy Citation Tools Deep Learning-Based Spatial Profiling Identifies MET-Associated Immune Exclusion and Therapeutic Vulnerability Underlying Racial Disparities in Head and Neck Cancer Xinyu Cui , Fanghui Chen , Ashley McCook-Veal , Yuan Liu , Nicole C. Schmitt , Christine H. Chung , Conor E. Steuer , Dong M. Shin , Nabil F. Saba , Yong Teng medRxiv 2026.10.26.26366494; doi: https://doi.org/10.64898/2026.10.26.26366494 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (637) Allergy and Immunology (915) Anesthesia (348) Cardiovascular Medicine (4962) Dentistry and Oral Medicine (492) Dermatology (425) Emergency Medicine (674) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1678) Epidemiology (16187) Forensic Medicine (36) Gastroenterology (1237) Genetic and Genomic Medicine (7236) Geriatric Medicine (749) Health Economics (1092) Health Informatics (5245) Health Policy (1459) Health Systems and Quality Improvement (1819) Hematology (598) HIV/AIDS (1374) Infectious Diseases (except HIV/AIDS) (16449) Intensive Care and Critical Care Medicine (1197) Medical Education (693) Medical Ethics (156) Nephrology (742) Neurology (7540) Nursing (376) Nutrition (1118) Obstetrics and Gynecology (1291) Occupational and Environmental Health (1036) Oncology (3723) Ophthalmology (1083) Orthopedics (403) Otolaryngology (463) Pain Medicine (499) Palliative Medicine (143) Pathology (719) Pediatrics (1849) Pharmacology and Therapeutics (750) Primary Care Research (781) Psychiatry and Clinical Psychology (6081) Public and Global Health (9943) Radiology and Imaging (2507) Rehabilitation Medicine and Physical Therapy (1504) Respiratory Medicine (1263) Rheumatology (657) Sexual and Reproductive Health (796) Sports Medicine (595) Surgery (799) Toxicology (109) Transplantation (317) Urology (304)
## Related Clinical Research

- [Reanalysis of isotope-resolved metabolomics in patient-derived lung cancer tissue: treatment- and](https://medichelpline.com/clinical-feed/medrxiv-1-treatment-and-tissue-context-specific-isotope-labeling-patterns-in-patient.md)
- [FDA Oncology Approvals 2014–2025: Immunotherapy vs Non‑Immunotherapy Endpoints and Efficacy](https://medichelpline.com/clinical-feed/medrxiv-1-usfda-oncology-drug-approvals-from-2014-2025-comparing-non-immunotherapy-and.md)
- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)
- [Immune checkpoint inhibitor–induced diabetes in metastatic NSCLC: case report, management, and fol](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-immune-checkpoint-inhibitor-induced-diabetes-mellitus-in-metastatic-nsclc-a.md)
- [Beyond conventional biomarkers: editorial on novel biomarkers and combinatorial approaches for imm](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-editorial-beyond-conventional-biomarkers-unlocking-immunotherapy-response.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.